Avalyn Pharma is led by CEO Lyn Baranowski, who previously worked at Pearl Therapeutics, where she helped develop treatments ...
Abstract: Idiopathic Pulmonary Fibrosis (IPF) and Tuberculosis (TB) are both complicated diseases and gradually increasing their incidence rates worldwide. Some population-based studies reported that ...
Stocktwits on MSN
TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening
Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...
Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...
New Haven-based Trevi Therapeutics Inc. disclosed it is seeking to raise $150 million through a public stock offering to ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.
A protein called PIEZO1, which is linked to mechanical stress, may play a key role in driving pulmonary fibrosis, a study ...
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies ...
Cautionary Language Concerning Forward-Looking Statements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results